## **Trustees’ Annual Report for the period** 

## **From 01 April 2023  To 31 March 2024** 

## **Charity name: Liverpool International transplant Initiative** 

## **Charity registration number: 1157311** 

## **Objectives and Activities** 

||SORP reference||
|---|---|---|
|Summary of the purposes of<br>the charity as set out in its<br>governing document|Para 1.17|1. To promote transplantation in underprivileged<br>countries.<br>2. To facilitate the creation of transplant units in<br>these countries, including equipment and<br>expertise.<br>3. To help train local healthcare professionals in<br>the field of transplant.<br>4. To support travelling teams from Liverpool to<br>train and educate healthcare professionals in the<br>field of transportation.|
|Summary of the main<br>activities in relation to those<br>purposes for the public<br>benefit, in particular, the<br>activities, projects or services<br>identified in the accounts.|Para 1.17 and<br>1.19|Since its inception, the main activity of the charity<br>has been its work with Al Shifa Hospital, Gaza.<br>The collaborative charitable initiative between<br>these two organisations aims to establish a kidney<br>transplant programme serving the population of<br>Gaza. The specific aims of this project are to:<br><br><br>Establish a kidney transplantation programme<br>at Al Shifa Hospital in Gaza<br>Establish the framework which will regulate<br>transplant activity in Gaza<br>Over the life of the project the long and short-term<br>objectives have been as follows:<br><br><br>Long term plan is to establish a kidney<br>transplant programme in Gaza run by local<br>expertise.<br><br><br>To continue transplant activity with the<br>support from the Royal Liverpool Hospital<br>Transplant Unit until the Gaza programme is fully<br>independent.<br>This involves consultant transplant surgeons and<br>associated medical staff travelling to Gaza to carry|





|||out  surgery and provide expert teaching and<br>advice.|
|---|---|---|
|Statement confirming<br>whether the trustees have<br>had regard to the guidance<br>issued by the Charity<br>Commission on public<br>benefit|Para 1.18|Trustees have had regard to the guidance issued<br>by the Charity commission on public benefit.|



## **Additional information (optional)** You may choose to include further statements where relevant about: 

||<br>SORP reference||
|---|---|---|
|Policy on grant making|Para 1.38||
|Policy on social investment<br>including program related<br>investment|Para 1.38||
|Contribution made by<br>volunteers|Para 1.38||
|Other||Due to the current situation in Gaza the work of<br>the Charity has been suspended and we await a<br>resolution before any decision on the future of our<br>work can be made.|



## **Achievements and Performance** 

||SORP reference||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identifying the difference the<br>charity’s work has made to<br>the circumstances of its<br>beneficiaries and any wider<br>benefits to society as a<br>whole.|Para 1.20|Dialysis for end stage renal failure represents a<br>huge burden on society and healthcare budget.<br>Transplantation offers a better quality of life for<br>patients with end stage renal failure and a better<br>chance of being productive and keeping a job.<br>Also it offers longer survival in comparison to<br>dialysis. It is estimated that each dialysis patient<br>costs around $25-30.000 US dollars per year. The<br>course of kidney transplantation is estimated at<br>around $25,000 dollars for the first year and then<br>$3-5,000 dollars per year afterwards.<br>Kidney transplantation is the best treatment<br>option for patients with end stage renal failure.<br>Literature evidence indicates that kidney<br>transplantation offers a better quality of life<br>compared to dialysis and prolonged survival. Also|





it is established that kidney transplantation is the most cost effective modality of treatment of kidney failure. The number of patients who are on dialysis in Gaza are around 350 patients. Currently patients who require kidney transplantation have to travel abroad to have the procedure performed with an estimated cost of around $25,000 US dollars per patient. For most patients in Gaza that is not a viable option. With the Gaza population of 2 million plus it is estimated  that the need for kidney transplantation is around 75 transplants per year. 

## **Additional information (optional)** You may choose to include further statements where relevant about: 

|<br>Achievements against<br>objectives set|<br>Para 1.41|<br>This is a long term project set against a<br>background of political and funding issues.<br>However, to date there have been over 80<br>successful transplants performed by the team<br>providing incalculable benefits for those patients<br>and the training for clinicians in Gaza continues.|
|---|---|---|
|Performance of fundraising<br>activities against objectives<br>set|Para 1.41|There are no specific fund raising activities.|
|Investment performance<br>against objectives|Para 1.41|No Investments exist.|
|Other|||





## **Financial Review** 

|**Financial Review**|||
|---|---|---|
|Review of the charity’s<br>financial position at the end<br>of the period|Para 1.21|The Charity is funded on a voluntary basis and<br>only travel expenses are paid if the funding exists.|
|Statement explaining the<br>policy for holding reserves<br>stating why they are held|Para 1.22|No Policy exists|
|Amount of reserves held|Para 1.22|Nil|
|Reasons for holding zero<br>reserves|Para 1.22|Not Required|
|Details of fund materially in<br>deficit|Para 1.24|N/A|
|Explanation of any<br>uncertainties about the<br>charity continuing as a going<br>concern|Para 1.23|**-**|



## **Additional information (optional)** You may choose to include further statements where relevant about: 

|The charity’s principal<br>sources of funds (including<br>any fundraising)|Para 1.47|Donations|
|---|---|---|
|Investment policy and<br>objectives including any<br>social investment policy<br>adopted|Para 1.46|None|
|A description of the principal<br>risks facing the charity|Para 1.46|Access to Gaza is via permits obtained through<br>the WHO. Without these the work could not<br>continue. Within Gaza access to staff and hospital<br>facilities is provided by the Gaza Ministry of<br>Health as required.|
|Other||Since November 2023, no access to Gaza has<br>been possible and the work of the charity has<br>been suspended.|





## **Structure, Governance and Management** 

|Description of charity’s<br>trusts:||None|
|---|---|---|
|Type of governing document<br>(trust deed, royal charter)|Para 1.25||
|How is the charity<br>constituted?<br>(e.g unincorporated<br>association, CIO)|Para 1.25||
|Trustee selection methods<br>including details of any<br>constitutional provisions e.g.<br>election to post or name of<br>any person or body entitled<br>to appoint one or more<br>trustees|Para 1.25||



## **Additional information (optional)** 

## You may choose to include further statements where relevant about: 

|Policies and procedures<br>adopted for the induction and<br>training of trustees|Para 1.51||
|---|---|---|
|The charity’s organisational<br>structure and any wider<br>network with which the<br>charity works|Para 1.51||
|Relationship with any related<br>parties|Para 1.51||
|Other|||



## **Reference and Administrative details** 

|Charity name|Liverpool International transplant Initiative|
|---|---|
|Other name the charity uses|None|
|Registered charity number|1157311|
|Charity’s principal address|Ward 9c, Royal Liverpool University Hospital,<br>Prescot street , Liverpool, L7 8XP|
|||





## **Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20|**Trustee name**|**Trustee name**|**Office (ifany)**|**Office (ifany)**|**Dates acted if not for whole year**|**Dates acted if not for whole year**|
|---|---|---|---|---|---|---|
||Mr A Hammad||Chaiman||||
||Mr E Scraggs||Secretary/Trustee||||
||Mr C McKean||Trustee||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||
|||**Director name**|||||
||||||||
||||||||
||||||||
||||||||
||||||||
||||||||



Name of trustees holding title to property belonging to the charity 

**Trustee name Dates acted if not for whole year** 



## **Funds held as custodian trustees on behalf of others** 

Description of the assets None held in this capacity 

Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity’s objects 

Details of arrangements for safe custody and segregation of such assets from the charity’s own assets 

## **Additional information (optional)** 

**Names and addresses of advisers (Optional information)** 

**Type of adviser Name** 

**Name of chief executive or names of senior staff members (Optional information)** 

## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

## **Other optional information** 



## **Declarations** 

## **The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

**Signature(s)** LENA,nage **Full name(s)** Mr E F Scraggs **Position (eg Secretary, Chair, etc)** ~~Po~~ Secretary/Trustee **Date** 01/08/24 ~~Pr~~ 



**Charity Name No (if any) Liverpool International Transplant Initiative 1157311** 

||||||**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**|**Charity Name**<br>**No (if any)**<br>**Liverpool International Transplant Initiativepool International Transplant Initiativeool International Transplant Initiativeplant Initiativelant Initiative**<br>**1157311**||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
||||||**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>01/04/23<br>31/03/24<br>**For the period**<br>**from**<br>~~ee ee~~<br>~~ee~~|||||||||||||||**CC16a**|
|**Section A Receipts and payments**<br>~~a~~|||||||||||||||||||||
|||||||**Unrestricted**<br>**funds**||||**Restricted**<br>**funds**||||**Endowment**<br>**funds**|||**Total funds**|||**Last year**|
|||||||**to the nearest      £**|**to the nearest      £**|**to the nearest      £**||**to the nearest £**||||**to the nearest £**|||**to the nearest £**|||**to the nearest £**|
||**A1 Receipts**||||||||||||||||||||
||Brought forward|||||**10,432**||||**-**||||**-**|||**10,432**|||**-**|
||Donations|||||**260**|**260**|||**-**||||**-**|||**260**||||
|||||||||||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
||~~**_Sub total_**~~~~_(Gross income for AR)_~~||||~~_(Gross income for AR)_~~|**-**<br>**10,692**<br>~~_(Gross income for AR)_~~||||**-**<br>**-**||||**-**<br>**-**|||**-**<br>**10,692**|||**-**<br>**-**|
||||||||||||||||||||||
||**(see table).**||||||||||||||||||||
|||||||**-**|**-**|||**-**||||**-**|||**-**||||
||||~~**_Sub total_**~~|~~**_Sub total_**~~|~~**_Sub total_**~~|**-**<br>**-**|**-**<br>**-**|||**-**<br>**-**||||**-**<br>**-**|||**-**<br>**-**||**-**<br>**-**|**-**<br>**-**|
||||||||||||||||||||||
|||**_Total receipts_ **||||**10,692**||||**-**||||**-**|||**10,692**|||**-**|
||**A3 Payments**||||||||||||||||||||
||Bank Charges|||||**72**|**72**|||**-**||||**-**|||**72**|||**-**|
||repaid bank opening fee|||||||||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
|||||||**-**|**-**|||**-**||||**-**|||**-**|||**-**|
||||**_Sub total_ **|||**72**|**72**|||**-**||||**-**|||**72**|||**-**|
||**A4 Asset and investment**||||||||||||||||||||
|||||||**-**|**-**|||**-**||||**-**|||**-**||||
|||||||**-**|**-**|||**-**||||**-**|||**-**||||
||||**_Sub total_ **|||**-**|**-**|||**-**||||**-**|||**-**||**-**|**-**|
|||**_Total payments_ **||||**72**|**72**|||**-**||||**-**|||**72**|||**-**|
||**_Net of receipts/(payments)_                  10,620**<br>**-**<br>**-**<br>**10,620**<br>**-**<br>**A5 Transfers between funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**A6 Cash funds last year end**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**_Cash funds this year end_                  10,620**<br>**-**<br>**-**<br>**10,620**<br>**-**<br>~~==>>>~~||||||||||||||||||||





|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|**Section B Statement of assets and liabilities at the end of the period**<br>**Categories**<br>**Details**<br>**to nearest £**<br>**to nearest £**<br>**to nearest £**<br>**B1 Cash funds**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Agreement Error<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Endowment**<br>**funds**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>~~—~~|
|---|---|---|---|---|---|---|
|||||**Unrestricted**<br>**Restricted**||**Endowment**|
|||||**funds**<br>**funds**||**funds**|
|||**Details**||**to nearest £**<br>**to nearest £**||**to nearest £**|
|**B2 Other monetary assets**||||**-**<br>**-**||**-**|
|||||**-**<br>**-**||**-**|
|||||**-**<br>**-**||**-**|
|||||**-**<br>**-**||**-**|
|||||**-**<br>**-**||**-**|
|||||**-**<br>**-**||**-**|
|||**Details**||**Cost (optional)**<br>**Fund to which**<br>**asset belongs**||**Current value**<br>**(optional)**|
|**B3 Investment assets**|**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>~~——~~||||||
|||**Details**||**Cost (optional)**<br>**Fund to which**<br>**asset belongs**||**Current value**<br>**(optional)**|
|**B4 Assets retained for the**<br>**charity’s own use**|**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>~~oss~~||||||



**Details liability relates (optional) (optional) B5 Liabilities - - - - -** Signed by one or two trustees on Date of behalf of all the trustees Signature Print Name approval 01/08/24 Mr E F Scraggs Mr Abdul Hammad 01/08/24 ~~———~~ 

**Fund to which Amount due When due** 

